Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
BRIDGEWATER, N.J., July 12, 2017 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today that it will host an Analyst and Investor Day on Wednesday, July 19, 2017. The event is scheduled to take place from 8:30-11:45 AM Eastern Time in New York City, NY.
The agenda will include an overview of the Company’s development and pre-commercial plans for Amikacin Liposome Inhalation Suspension (ALIS), as well as an introduction to the Company’s Phase 2 candidate INS1007.
The program will also feature a presentation by Dr. Kevin L. Winthrop, MD, MPH, Professor at the School of Public Health, and Associate Professor in the Departments of Infectious Diseases and Ophthalmology at Oregon Health & Science University.
The event will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC), which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no approved inhaled products specifically indicated for the treatment of refractory NTM lung disease caused by MAC in the United States or the European Union. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of DPP1 with therapeutic potential in non-cystic fibrosis bronchiectasis, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.
"Insmed" and "ARIKAYCE" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.
Investor Contact: Laura Perry or Heather Savelle Argot Partners 212-600-1902 [email protected] [email protected]
